Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 401-420 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 401 | Vantor lowweak | Opp 1 Risk 1 | Thesis: Vantor's membership rationale suggests spatial-intelligence and constellation expansion relevance, but there are no retained evidence or article summaries within the recent evidence window to support a current opportunity thesis. Why now: Why now is weak because the reviewed sources contain no retained post-cutoff directional evidence. Caveats: Coverage debug shows articles after recent evidence window 0 and evidence after recent evidence window 0. Membership rationale references article IDs without and cannot be cited directly here. |
| 402 | Varda Space Industries lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources confirms cohort relevance, but it contains no retained 90-day direct positive evidence to support a durable 1 year+ upside thesis. Why now: No within the recent evidence window company-specific evidence were available after filtering; articles after recent evidence window and evidence after recent evidence window are both zero in coverage data, so recency-based thesis formation is not supported in these reviewed sources. Caveats: 12 articles were considered historically, but zero article IDs remained after the 90-day recent evidence filter. Membership rationale cites older support article IDs but those underlying evidence are not retained in the served reviewed sources. Scores are constrained by evidence absence, not by a documented negative business development. |
| 403 | Venturi Astrolab lowweak | Opp 1 Risk 1 | Thesis: The phase-2 rationale references NASA moon buggy contracts and moon base planning tied to articles: and: which could have supported an opportunity case, but these reviewed sources provide no representative article details, or retained evidence after recent evidence window. Therefore no grounded positive thesis can be advanced here. Why now: Why now is weak because despite 30 articles considered, coverage data shows articles after recent evidence window of 0 and evidence recent evidence review kept_rows of 0, so the reviewed sources does not preserve dated supporting evidence inside the 90-day window. Caveats: Phase-2 rationale cannot substitute for cited article evidence because are absent. No direct positive or negative evidence arrays are populated. Low scores are driven by evidence retention limits in these reviewed sources. |
| 404 | Virgin Galactic Holdings, Inc. lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources does not provide direct positive evidence inside the scoring fields, so no positive investment thesis is supportable here. Why now: The phase2 rationale references three article IDs, but the reviewed sources includes no representative article summaries or evidence to cite for a dated catalyst. Coverage data shows zero article IDs after recent evidence window and zero available evidence, so the current-state thesis is unsupported by reviewed sources detail. Caveats: Do not infer direction from company identity or sector relevance alone. Phase2 membership support cannot substitute for direct thesis evidence. |
| 405 | Vyoma GmbH lowweak | Opp 1 Risk 1 | Thesis: Insufficient admissible reviewed sources evidence to support a positive thesis within the selected recent evidence window, even though membership rationale says Vyoma is an SDA company selected by ESA and flying SSA sensors. Why now: Why now is unsupported because the reviewed sources contain no surviving evidence after recent evidence filtering; timing and business-state changes cannot be validated from the provided material. Caveats: Zero evidence after recent evidence filtering. Membership rationale alone is not sufficient for directional scoring. No direct dated catalyst or adverse development is provided. |
| 406 | Windward Ltd. lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources provide no direct positive company-specific evidence after recent evidence window. The only described context is that Vantor partnered with Windward for maritime awareness, but relations are context-only unless separately gated and cannot be used as counterparty propagation evidence. Why now: No catalyst is established. Coverage debug shows 27 article IDs considered but 0 after recent evidence window and 0 evidence available. Caveats: Membership rationale references article ID: but no is provided in the reviewed sources, so it cannot be cited as factual scoring evidence under the the evidence standard. Relation context is explicitly weaker and not valid counterparty propagation evidence. |
| 407 | WISeKey International Holding Ltd lowweak | Opp 1 Risk 1 | Thesis: The reviewed sources indicates space-related operations through WISeSat, but provides no retained within the recent evidence window direct positive evidence or article to support an opportunity thesis. Why now: There are zero available evidence after recent evidence window for ranking, so no evidence-backed timing signal is available. Caveats: Membership support mentions 21 LEO satellites launched and operational space-related infrastructure, but those claims are not accompanied here by retained ranking evidence or article. Without dated evidence inside the recent evidence window, score should remain low-conviction. |
| 408 | York Space Systems lowweak | Opp 1 Risk 1 | Thesis: The membership rationale references public listing status and defense contract momentum, but no retained within the recent evidence window direct evidence or article summaries are available here to support a positive thesis. Why now: The reviewed sources have no retained dated evidence after the 90-day recent evidence window, so there is no citable timing edge for a 1 year+ ranking. Caveats: Coverage is effectively empty after recent evidence window: articles after recent evidence window = 0 and evidence after recent evidence window = 0. Membership rationale cites article IDs and, but no or retained evidence text are provided here. Later-dated evidence could supersede older listing or contract-status claims, but no such retained evidence exists in these reviewed sources. |
| 409 | York Space Systems lowweak | Opp 1 Risk 1 | Thesis: The membership rationale suggests meaningful satellite-manufacturing and tactical-communications activity, but the reviewed sources retains no direct evidence within the recent evidence window to support a positive thesis. Why now: Although membership support cites articles, and: no representative summaries or retained evidence are included here, leaving no current catalyst basis. Caveats: 54 articles considered, but 0 retained after recent evidence filtering. Cannot elevate based on membership rationale alone. |
| 410 | Akashalabdhi lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable because the reviewed sources contain no direct positive evidence for Akashalabdhi within the recent evidence window. Why now: There is no visible near-term or long-horizon company-specific catalyst in the reviewed sources. The membership review explicitly says the only included article does not mention Akashalabdhi in the visible summary, and coverage debug shows zero articles and zero evidence after recent evidence window. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article. Evidence recent evidence review shows 0 kept rows after the March 29, 2026 cutoff. The reviewed sources itself says visible evidence is insufficient to determine even qualifying membership. |
| 411 | Amentum Holdings Inc. lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable from retained reviewed sources evidence because there are no direct positive evidence and no articles retained after the 90-day recent evidence window. Why now: No current catalyst is evidenced in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window despite large historical mention volume. Caveats: Phase-2 rationale references article IDs and, but no article summaries or retained evidence are included here. Historical aerospace exposure does not create a current directional thesis without retained evidence. |
| 412 | Apparition Geoservices GmbH lowweak | Opp 0 Risk 0 | Thesis: No positive thesis can be established because no direct positive evidence for Apparition Geoservices GmbH is available in the reviewed sources after recent evidence filtering. Why now: No current business-state change or catalyst is visible. Although 6 articles were considered, coverage debug shows 0 articles after recent evidence window and 0 evidence after recent evidence window, while the membership review says the reviewed sources are only a broad European tech funding roundup without a direct company-specific description. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Mention count and article count do not increase conviction because no post-recent evidence window evidence are available. Review-status rationale says retrieval context is insufficient for membership. |
| 413 | Arkeon lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supported because Arkeon has no direct positive evidence in the reviewed sources within the selected recent evidence window. Why now: No company-specific timing signal is visible. Coverage debug shows zero post-recent evidence window articles and evidence, and the membership note says only a generic funding-roundup article was available without a company-specific description tying Arkeon to the scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct event, fact, or negative development is available after recent evidence window. Low membership confidence is not directional evidence. |
| 414 | Ars Magna Semiconductors lowweak | Opp 0 Risk 0 | Thesis: No positive thesis can be formed because the reviewed sources includes no direct positive evidence for Ars Magna Semiconductors within the recent evidence window. Why now: There is no visible long-horizon strategic catalyst in the usable evidence. Coverage debug shows zero post-recent evidence window articles and evidence, and the only cited support is a general tech funding roundup without a company-specific description linking the company to the scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct positive or adverse operating evidence is available. Generic roundup context is weaker than company-specific evidence and is not directional proof. |
| 415 | Augusta Labs lowweak | Opp 0 Risk 0 | Thesis: No positive thesis is supportable because the reviewed sources have no direct positive evidence for Augusta Labs after recent evidence filtering. Why now: No current or durable catalyst can be identified from the reviewed sources. Coverage debug shows zero post-recent evidence window articles and evidence, and the membership note says the company is only present in a generic funding-roundup article without direct identification against the listed criteria. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Absence of risk evidence is not positive evidence. No direct company-specific facts or events are available. |
| 416 | BeatpulseLabs lowweak | Opp 0 Risk 0 | Thesis: No positive thesis can be justified because no direct positive evidence for BeatpulseLabs is present in the reviewed sources within the recent evidence window. Why now: There is no visible catalyst or deterioration signal. Coverage debug shows zero post-recent evidence window articles and evidence, and the only cited support is a generic funding-roundup article with no direct company-specific connection to the scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article No direct event or fact evidence is available after recent evidence window. Generic context should not be treated as directional proof. |
| 417 | Bluestaq lowweak | Opp 0 Risk 1 | Thesis: No positive thesis is supported. The reviewed sources say Bluestaq is mentioned only through an executive's prior role at the company, which is indirect context rather than company-specific business evidence (: unavailable in reviewed sources). Why now: There is no clear why-now catalyst because the only reference is an indirect executive-background mention, with no direct event, product, contract, or financing evidence available. Caveats: No current evidence is provided for Indirect mention via an executive's prior role is not direct company evidence. Zero evidence available after recent evidence window. |
| 418 | Bose Corporation lowweak | Opp 0 Risk 0 | Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Bose Corporation after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 97 articles considered but 0 articles after recent evidence window and 0 evidence available after dedupe; despite broad article consideration, nothing survived the time/evidence filters for a 1 year+ thesis judgment. Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 419 | Breaking Change lowweak | Opp 0 Risk 0 | Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Breaking Change after the 90-day recent evidence window. Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 3 articles considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable. Caveats: Phase-2 membership rationale says the reviewed sources gives no meaningful company-specific evidence and references: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept. |
| 420 | CameraMatics lowweak | Opp 0 Risk 0 | Thesis: No positive thesis can be supported because there is no direct positive evidence for CameraMatics in the reviewed sources after recent evidence filtering. Why now: No company-specific catalyst is visible despite 6 articles considered, because coverage debug shows 0 articles after recent evidence window and 0 evidence after recent evidence window. The membership note says the reviewed sources only includes CameraMatics in a generic funding roundup with no direct statement tying it to the scope. Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Article count does not create conviction because no post-recent evidence window evidence are available. No direct positive or adverse company-specific event is available. |
Risk view
Showing rows 81-100 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 81 | Interlune lowweak | Opp 5 Risk 3 | Thesis: The company also carries execution risk because the reviewed sources provide no further retained evidence on milestone completion, follow-on awards, commercialization timing, or technical results. A single contract supports relevance but does not prove scalable economics. Why now: The key 'why now' is the cited NASA contract in article: but the reviewed sources does not include the article summary or, so exact date and latest status are not visible here. Caveats: Opportunity case relies on membership rationale rather than included direct article evidence. A $6.9M contract is positive validation, but contract size alone may not be enough to de-risk a lunar-resource business. No negative evidence is provided, so risk mostly reflects execution uncertainty. |
| 82 | IonQ lowweak | Opp 3 Risk 3 | Thesis: Risk stems from thesis leakage: the reviewed sources frames IonQ primarily as parent/acquirer, while the strongest space-specific evidence appears to sit at subsidiary level, so investors could overstate IonQ's direct space-business impact based on insufficient company-specific proof. Why now: Potential 'why now' would be the referenced space-subsidiary contract pathway, but recency and direct materiality to IonQ are not validated in available evidence for the 90-day recent evidence window. Caveats: Phase-2 rationale references and: but no or summaries are provided in the reviewed sources. Relations and counterparty propagation are not allowed by default. Coverage debug shows zero evidence after recent evidence window despite a large article universe. |
| 83 | Iridium Communications Inc. lowmedium | Opp 5 Risk 3 | Thesis: Risk is moderate-low because there is no direct adverse evidence, but the reviewed sources lack recent company-specific contract, financing, or product milestone catalysts, so the case depends more on strategic position than on fresh business acceleration. Why now: The current support is an April 3, 2026 article-level overview of Iridium’s constellation and service footprint rather than a new event, so timing fit is only medium. Evidence
Caveats: Evidence is supporting article context, not a fresh contract or earnings-linked milestone. |
| 84 | Kepler mediummedium | Opp 6 Risk 3 | Thesis: Risk remains moderate because the evidence is primarily a company-source article and supporting article context rather than independent dated event evidence. The reviewed sources show no adverse developments, but also limited third-party confirmation. Why now: The latest visible evidence is dated June 23, 2026, making the milestone recent within the 90-day recent evidence window. The article explicitly frames this as the beginning of an operational network, which is more relevant to a 1 year+ horizon than a short-lived announcement. Evidence
Caveats: Primary evidence is from Kepler's own site. No direct contract, revenue, or financing detail is provided in the visible evidence. Same article appears in both representative and weak-context forms, which is not independent confirmation. |
| 85 | Kepler Aerospace lowweak | Opp 3 Risk 3 | Thesis: There is no direct negative evidence available. The main risk is that the business description is broad but unsupported by current, citable post-recent evidence window evidence, leaving commercialization and scale uncertain. Why now: No current catalyst is established. Membership support references article ID: but the reviewed sources provide no and shows no evidence after recent evidence window. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources provide no or article summary. Context includes relation/fact counts in support statistics, but relations are context-only and cannot be propagated as operating proof. |
| 86 | L3Harris Technologies mediummedium | Opp 6 Risk 3 | Thesis: Risk is lower than many peers in these reviewed sources because there is no cited direct adverse evidence, but the ranking is capped by limited fresh company-specific evidence within the 90-day window and reliance on supporting article context rather than detailed award economics attributable specifically to L3Harris. Why now: The recent timing anchor is the April 8, 2026 Andromeda article. Older 2020 MOSSAIC history exists in the reviewed sources but should not drive the current timing view because it is outside the recent evidence window and materially older than the current contract context. Evidence
Caveats: Current opportunity case depends on supporting article context rather than available direct positive events. The reviewed sources includes an older 2020 contract article, but that is not recent support for 'why now'. |
| 87 | Loft Orbital mediummedium | Opp 7 Risk 3 | Thesis: Risk exists because the positive case is largely supporting article context from external supporting source sources rather than direct dated events in the reviewed sources, and execution remains significant given a 10-satellite constellation deployment and launch timeline. But there is no retained material adverse evidence. Why now: Why now is credible for a 1 year+ horizon because several dated articles from 2026 establish a recent contract win and near-forward deployment timeline: Loft announced on April 30, 2026 a multi-year CNES contract worth up to tens of millions of euros with first satellite scheduled to launch in Q4 2026. Via Satellite on May 1, 2026 described a 10-satellite EO constellation under that contract. SpaceNews on May 5, 2026 said Loft is expanding into 'full-service constellation deals'. Evidence
Caveats: Most retained support is supporting article context, which the reviewed sources treats as bounded context and weaker than direct dated event/fact evidence. Several favorable funding articles for Loft are dated January 2025 and were dropped by the 90-day recent evidence window, so they should not drive the current score. Execution risk remains around deploying the constellation and meeting the stated 2026 launch timing. |
| 88 | MDA Space Ltd. lowweak | Opp 4 Risk 3 | Thesis: Risk is moderate because the available evidence is entirely undated external article context, making recency and state-of-business uncertain. Why now: Why-now is weak because both available representative articles are undated, so current timing and whether these items remain incremental versus already absorbed is uncertain Evidence
Caveats: Both cited articles are undated; recency is uncertain. Support is weak and based on article context, not direct positive events. No material adverse evidence is available, but no strong current catalyst is validated either. |
| 89 | Modul8 lowweak | Opp 4 Risk 3 | Thesis: Risk remains moderate because the reviewed sources supplies no available positive evidence after recent evidence window to confirm timing, contract status, or deployment progress; mission-heavy lunar communications programs can be timing-sensitive, but these reviewed sources gives no adverse proof either. Why now: Among sparse names, the stated combination of funding plus lunar communications program exposure could matter over 1 year+, but recency cannot be validated from served evidence. Caveats: The strongest claims are only in membership rationale and not backed by citeable -bearing evidence in the reviewed sources. No negative evidence does not equal low fundamental risk. |
| 90 | Muon Space lowweak | Opp 3 Risk 3 | Thesis: Risk is balanced with opportunity because the available evidence is mostly weak supporting article context rather than direct contract, financing, or milestone evidence, leaving business traction and near-medium term scaling uncertain. Why now: The most recent dated context is a May 22, 2026 job posting indicating contracting and legal operations needs, which may imply organizational buildout but is weak evidence for a major catalyst. Evidence
Caveats: The reviewed sources contain no direct positive or negative company-specific events. The May 22, 2026 job posting is operational context, not proof of revenue or contracts. Citation |
| 91 | NordSpace Corp. lowweak | Opp 3 Risk 3 | Thesis: No direct adverse evidence is available, but development-stage rocket businesses carry obvious execution dependency; in these reviewed sources that risk cannot be upgraded to high because the evidence does not show a specific setback, only insufficient current confirmation. Why now: The only directional clue is the membership-support article reference: but the reviewed sources includes no, no summary, and no available post-recent evidence window evidence, so timing and durability are uncertain. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources provide no or article summary. Opportunity case relies on generic funding support mention without current milestone evidence. |
| 92 | Northrop Grumman Corp mediumstrong | Opp 8 Risk 3 | Thesis: Risk is present but comparatively modest in the reviewed sources because no material adverse event is cited. The main risk is that the evidence is largely supporting article context and program participation, so exact economic contribution, timing, and competitive share are not fully established here. Why now: The setup is current and cumulative: April 8, 2026 Andromeda participation, June 1, 2026 Golden Dome interceptor partnership, and June 22, 2026 award of a $398M protected satcom contract all fall within the 90-day recent evidence window and point to sustained momentum. Evidence
Caveats: The reviewed sources does not provide direct business impact breakdowns beyond the $398M contract article. Some support is supporting article context rather than dated events. |
| 93 | NorthStar Earth & Space lowweak | Opp 4 Risk 3 | Thesis: Risk is moderate because evidence coverage is very thin, and the reviewed sources offers mainly context that the company planned to go public via SPAC, without stronger direct proof on operational milestones or contract conversion in this company row. Why now: The only dated evidence in this row is an April 27, 2026 article-level summary stating NorthStar Earth & Space plans to go public in a SPAC deal at a $300 million valuation. That may matter over a 1 year+ horizon, but the reviewed sources does not provide stronger company-specific direct evidence here. Evidence
Caveats: Coverage is extremely thin in this row: only one external article and no direct positive or negative dated events. The phase-2 rationale mentions a CAD$40M+ Royal Canadian Air Force contract, but that contract evidence is not directly surfaced in the available evidence fields for this output row, so it should not be elevated beyond the membership rationale. |
| 94 | Open Cosmos mediummedium | Opp 7 Risk 3 | Thesis: Risk is present but not strongly evidenced as negative news. The main risks are that the evidence is supporting article context rather than direct events, and one supporting item concerns spacecraft supply to a military mission rather than direct revenue or contract award to Open Cosmos. Why now: The timing is favorable for a 1 year+ horizon because the latest dated evidence on June 17, 2026 indicates market entry and operation of the first telecom satellites, which can matter over a multi-quarter rollout period. A prior April 8, 2026 article also shows Open Cosmos spacecraft being used in the Orpheus UK military mission, adding defense-adjacent relevance. These dates are source dates extracted from the article summaries. Evidence
Caveats: Evidence is external article context and weak-context rows, not direct positive events. Same-article repeated rows are not independent confirmation. |
| 95 | Orbital lowweak | Opp 4 Risk 3 | Thesis: Risk is also meaningful because the same article describes an early-stage startup with only a $5 million pre-seed raise pursuing an extremely ambitious plan involving an in-orbit demo next year and more than 100,000 orbital data centers, which raises execution and scale risk, although this is supporting article context rather than direct adverse evidence, June 10, 2026). Why now: The recency is relatively fresh: the is based on June 10, 2026, inside the 90-day recent evidence window, and it frames both new capital and a next-year demo as near-to-medium-term strategic milestones. Evidence
Caveats: All retained evidence is weak context supporting article context; there is no direct positive event/fact available. Same-article repeated rows are not independent confirmation. The opportunity case depends on an early-stage roadmap and financing announcement; commercial traction is not directly evidenced in retained rows. |
| 96 | Orbital Recovery Crew lowweak | Opp 3 Risk 3 | Thesis: Risk is also material because the evidence is limited to the company's own site and supporting article context, with no independent retained event evidence for contracts, missions, financing, customers, or regulatory outcomes; the same page also conditions service availability on manifest availability and continuing cooperation of regulatory bodies. Why now: The only retained evidence is a page with May 21, 2026, within the 90-day window, indicating recent discoverable claims of operations and service scope, but not a third-party validated catalyst. Evidence
Caveats: Evidence is company-site article context, not independent confirmation. No direct positive or negative dated events are available. Same-article repeated rows are not independent confirmation. |
| 97 | Overview Energy lowweak | Opp 4 Risk 3 | Thesis: The technology area appears highly ambitious and execution-sensitive, but no direct negative evidence is provided in the reviewed sources. Why now: The likely catalyst is the reported Air Force contract, yet the reviewed sources gives no retained article summary or evidence row to establish recency or contract scale. Caveats: Phase2 membership rationale references: but no article summary or evidence are available. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 98 | Pacific Defense lowweak | Opp 4 Risk 3 | Thesis: Despite the favorable context, the reviewed sources contain no post-recent evidence window evidence, no -backed article summary, and no fresh proof of follow-on contracts or operational success after the demo; that limits conviction and leaves execution risk unresolved. Why now: The company appears more advanced than several peers because the reviewed sources references an on-orbit demo under contract, but there is no citable recency signal beyond membership support article ID: and no available evidence after recent evidence window. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources provide no or article summary for citation. Opportunity score is relative within a weak-evidence batch, not high absolute conviction. |
| 99 | Payload Aerospace, S.A. lowweak | Opp 2 Risk 3 | Thesis: Main risk is evidence opacity and recency uncertainty rather than documented adverse events. The reviewed sources show one article considered but zero article IDs after recent evidence window and zero evidence available after recent evidence window, so business-state visibility is poor. Why now: Why now is weak because the reviewed sources' coverage debug shows zero article IDs after the March 29, 2026 cutoff and zero evidence after recent evidence window; any older fundraising context may no longer capture current business state. See support references listing article in the membership rationale, but no or article detail is provided in the reviewed sources, so recency and context cannot be independently assessed. Caveats: No -bearing article detail is provided for the fundraising support article, so factual claims beyond the membership rationale cannot be expanded. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0, limiting confidence. |
| 100 | Planet Labs PBC lowweak | Opp 3 Risk 3 | Thesis: Risk is moderate because the reviewed sources lack recent direct evidence on contracts, growth, financing, or setbacks, leaving the current business trajectory uncertain. Why now: Why-now is weak: the only in-window evidence is an April 5, 2026 startup-listing article describing Planet as operating its own satellite constellation and geospatial analytics platform, which is durable context but not a clear catalyst. Evidence
Caveats: Evidence is only supporting article context, not direct company event or fact evidence with strong materiality. No direct positive or negative dated events are available. This is a low-conviction watchlist name in these reviewed sources. |